Nuveen LLC Buys New Shares in ZimVie Inc. $ZIMV

Nuveen LLC bought a new stake in ZimVie Inc. (NASDAQ:ZIMV) in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 83,423 shares of the company’s stock, valued at approximately $901,000. Nuveen LLC owned 0.30% of ZimVie as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC grew its stake in ZimVie by 5.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,127 shares of the company’s stock worth $211,000 after buying an additional 836 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in shares of ZimVie by 8.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,571 shares of the company’s stock worth $343,000 after buying an additional 1,852 shares in the last quarter. Wells Fargo & Company MN grew its position in ZimVie by 17.8% in the fourth quarter. Wells Fargo & Company MN now owns 17,037 shares of the company’s stock valued at $238,000 after purchasing an additional 2,569 shares in the last quarter. Monarch Capital Management Inc. boosted its position in ZimVie by 6.3% during the first quarter. Monarch Capital Management Inc. now owns 69,700 shares of the company’s stock valued at $753,000 after purchasing an additional 4,140 shares during the last quarter. Finally, Deutsche Bank AG raised its stake in ZimVie by 61.7% in the fourth quarter. Deutsche Bank AG now owns 23,796 shares of the company’s stock valued at $332,000 after buying an additional 9,084 shares during the period. Institutional investors and hedge funds own 95.63% of the company’s stock.

ZimVie Trading Up 0.3%

Shares of ZIMV opened at $18.94 on Wednesday. The business’s 50-day moving average price is $15.42 and its 200-day moving average price is $12.02. The stock has a market cap of $534.11 million, a PE ratio of -27.06 and a beta of 2.19. The company has a quick ratio of 1.60, a current ratio of 2.37 and a debt-to-equity ratio of 0.56. ZimVie Inc. has a twelve month low of $8.15 and a twelve month high of $19.01.

ZimVie (NASDAQ:ZIMV) last announced its earnings results on Wednesday, July 30th. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.21 by $0.05. The business had revenue of $116.66 million for the quarter, compared to the consensus estimate of $112.60 million. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. On average, equities analysts forecast that ZimVie Inc. will post 0.6 EPS for the current fiscal year.

Analyst Ratings Changes

ZIMV has been the subject of several research analyst reports. UBS Group reduced their target price on shares of ZimVie from $16.00 to $10.00 and set a “neutral” rating for the company in a report on Thursday, May 15th. Barclays raised shares of ZimVie from an “underweight” rating to an “equal weight” rating and boosted their target price for the stock from $9.00 to $19.00 in a research note on Tuesday, July 22nd. B. Riley lowered shares of ZimVie from a “buy” rating to a “neutral” rating and set a $19.00 price target on the stock. in a report on Thursday, July 31st. Finally, Wall Street Zen downgraded shares of ZimVie from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Four equities research analysts have rated the stock with a Hold rating, According to MarketBeat, ZimVie currently has a consensus rating of “Hold” and an average target price of $17.75.

ZimVie Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.